The FDA granted BioMarin orphan status for its treatment of Duchenne muscular dystrophy. Reference Link
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BMRN:
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- BioMarin initiated with an Underperform at Bernstein
- Tenaya Therapeutics price target lowered to $24 from $28 at Chardan
- BioMarin: FDA accepts sNDA to expand use of VOXZOGO for injection